Other studies presented during ACC 2019


Other studies presented during ACC 2019

  • GLASSY, a sub-study of the GLOBAL LEADERS trial in which blinded event adjudication was performed evaluating the impact of Ticagrelor monotherapy vs standard DAPT. Ticagrelor monotherapy ultimately showed non-inferiority as compared to DAPT, and a reduction of MI and ST was evident at landmark analysis beyond 12 months.
  • TICAGRELOR REVERSAL: data regarding the first reversal agent of Ticagrelor, tested in a phase 1 setting, showed a consistent reversal of platelet inhibition in roughly 5 minutes after infusion. The study has been simultaneously published in the NEJM.
  • MRUSMI: evaluated the effect of sonothrombolysis during primary percutaneous coronary intervention. The authors studied this interesting strategy ultimately finding a reduction of the primary endpoint and a better ejection fraction at cardiac MRI with the experimental treatment. The study has been simultaneously published in JACC.